APAC Breast Cancer Diagnostics Market - Industry Trends and Forecast to 2030

Description

List of Tables

Asia-Pacific breast cancer diagnostics market is projected to register a CAGR of 10.3% in the forecast period of 2023 to 2030. The new market report contains data for historic year 2021, the base year of calculation is 2022 and the forecast period is 2023 to 2030.

Market Segmentation:

Asia-Pacific Breast Cancer Diagnostics Market, By Test Type (Imaging, Biopsy, Genomic Test, Blood Test, and Others), Type (Ductal In Situ Carcinoma, Invasive Ductal Carcinoma, Inflammatory Breast Cancer, and Metastatic Breast Cancer), End User (Hospitals, Clinics, Research and Academic Institutes, Diagnostic Centres, and Others) Distribution Channel (Direct Tender, Retail Sales, and Others), Country (China, Japan, India, Australia, South Korea, Singapore, Malaysia, Thailand, Indonesia, Philippines, Rest of Asia-Pacific) Industry Trends and Forecast to 2030.

Some of the major factors contributing to the growth of the Asia-Pacific breast cancer diagnostics market are:

Increasing breast cancer patients among the women population as well as men

Rise in technological advancement for breast cancer diagnostic

Market Players

The key market players operating in the Asia-Pacific breast cancer diagnostics market are:

Provista Diagnostics

Thermo Fisher Scientific Inc.

Myriad Genetics, Inc.

Illumina, Inc.

Bio-Rad Laboratories, Inc.

NanoString.

Cepheid

BIOMERIEUX

1 INTRODUCTION 48

1.1 OBJECTIVES OF THE STUDY 48
1.2 MARKET DEFINITION 48
1.3 OVERVIEW OF THE ASIA PACIFIC BREAST CANCER DIAGNOSTIC MARKET 48
1.4 CURRENCY AND PRICING 50
1.5 LIMITATIONS 50
1.6 MARKETS COVERED 50

2 MARKET SEGMENTATION 54

2.1 MARKETS COVERED 54
2.2 GEOGRAPHICAL SCOPE 55
2.3 YEARS CONSIDERED FOR THE STUDY 56
2.4 DBMR TRIPOD DATA VALIDATION MODEL 57
2.5 PRIMARY INTERVIEWS WITH KEY OPINION LEADERS 60
2.6 MULTIVARIATE MODELLING 61
2.7 MARKET END USER COVERAGE GRID 62
2.8 TEST TYPE LIFELINE CURVE 63
2.9 DBMR MARKET POSITION GRID 64
2.10 VENDOR SHARE ANALYSIS 65
2.11 SECONDARY SOURCES 66
2.12 ASSUMPTIONS 66

3 EXECUTIVE SUMMARY 67

4 PREMIUM INSIGHTS 69

4.1 PESTEL ANALYSIS 70
4.2 PORTER'S 5 FORCES 71

5 EPIDEMIOLOGY 72

6 INDUSTRIAL INSIGHTS 73

7 REGULATORY FRAMEWORK 74

8 MARKET OVERVIEW 76

8.1 DRIVERS 78
- 8.1.1 LAUNCH OF TECHNOLOGICALLY ADVANCED DIAGNOSIS & THERAPEUTICS TO AID GROWTH 78
- 8.1.2 INCREASING PREVALENCE OF BREAST CANCER 78
- 8.1.3 GROWING IMPORTANCE OF WOMEN'S HEALTH 79
- 8.1.4 RISING AWARENESS TOWARDS THE BREAST CANCER 79
8.2 RESTRAINTS 80
- 8.2.1 ADVERSE EFFECTS OF BREAST CANCER THERAPEUTICS 80
- 8.2.2 HIGH COST OF THE IMAGING SYSTEMS 80
8.3 OPPORTUNITIES 81
- 8.3.1 INITIATIVES TAKEN BY THE GOVERNMENT 81
- 8.3.2 STRATEGIC INITIATIVES TAKEN BY THE KEY MARKET PLAYERS 81
- 8.3.3 GROWTH IN RESEARCH AND DEVELOPMENT OF BREAST CANCER 82
8.4 CHALLENGES 82
- 8.4.1 LACK OF DIAGNOSTIC INFRASTRUCTURE 82
- 8.4.2 LACK OF SKILLED PROFESSIONALS FOR PROPER DIAGNOSIS OF BREAST CANCER 83

9 ASIA PACIFIC BREAST CANCER DIAGNOSTICS MARKET, BY TEST TYPE 84

9.1 OVERVIEW 85
9.2 IMAGING 88
- 9.2.1 IONIZING BREAST IMAGING TECHNOLOGIES 89
  - 9.2.1.1 FULL-FIELD DIGITAL MAMMOGRAPHY (FFDM) 90
  - 9.2.1.2 ANALOG MAMMOGRAPHY 90
  - 9.2.1.3 3D BREAST TOMOSYNTHESIS 90
  - 9.2.1.4 POSITRON EMISSION TOMOGRAPHY/ COMPUTED TOMOGRAPHY (PET/CT) 90
  - 9.2.1.5 MOLECULAR BREAST IMAGING/ BREAST SPECIFIC GAMMA IMAGING (MBI/BSMI) 90
  - 9.2.1.6 POSITRON EMISSION MAMMOGRAPHY 90
  - 9.2.1.7 OTHERS 90
- 9.2.2 NON-IONIZING IMAGING TECHNOLOGIES 90
  - 9.2.2.1 OPTICAL IMAGING 91
  - 9.2.2.2 BREAST ULTRASOUND 91
  - 9.2.2.3 BREAST MRI (MAGNETIC RESONANCE IMAGING) 91
  - 9.2.2.4 AUTOMATED WHOLE BREAST ULTRASOUND (AWBU) 91
  - 9.2.2.5 BREAST THERMOGRAPHY 92
- 9.2.3 BIOPSY 92
  - 9.2.3.1 SURGICAL BIOPSY 93
  - 9.2.3.2 FINE NEEDLE ASPIRATION BIOPSY 93
  - 9.2.3.3 CORE NEEDLE BIOPSY 93
  - 9.2.3.4 IMAGE-GUIDED BIOPSY 93
  - 9.2.3.5 SENTINEL LYMPH NODE BIOPSY 94
- 9.2.4 GENOMIC TEST 94
  - 9.2.4.1 MOLECULAR TESTING 95
    - 9.2.4.1.1 PD-L1 96
    - 9.2.4.1.2 MICROSATELLITE INSTABILITY-HIGH (MSI-H) OR DNA MISMATCH REPAIR DEFICIENCY (DMMR) 96
    - 9.2.4.1.3 NTRK GENE FUSIONS 96
    - 9.2.4.1.4 PI3KCA GENE MUTATION 96
  - 9.2.4.2 MAMMAPRINT 96
  - 9.2.4.3 ONCOTYPE DX 96
  - 9.2.4.4 OTHERS 96
9.3 BLOOD TEST 97
9.4 OTHERS 98

10 ASIA PACIFIC BREAST CANCER DIAGNOSTICS MARKET, BY TYPE 99

10.1 OVERVIEW 100
10.2 INVASIVE DUCTAL CARCINOMA 103
10.3 DUCTAL CARCINOMA IN SITU 103
10.4 INFLAMMATORY BREAST CANCER 104
10.5 METASTATIC BREAST CANCER 105

11 ASIA PACIFIC BREAST CANCER DIAGNOSTICS MARKET, BY END USER 106

11.1 OVERVIEW 107
11.2 HOSPITALS 109
11.3 DIAGNOSTICS CENTERS 110
11.4 CLINICS 111
11.5 RESEARCH & ACADEMIC INSTITUTES 111
11.6 OTHERS 112

12 ASIA PACIFIC BREAST CANCER DIAGNOSTICS MARKET, BY DISTRIBUTION CHANNEL 114

12.1 OVERVIEW 115
12.2 DIRECT TENDER 118
12.3 RETAIL SALES 118
12.4 OTHERS 119

13 ASIA PACIFIC BREAST CANCER DIAGNOSTICS MARKET, BY REGION 120

13.1 ASIA-PACIFIC 121
- 13.1.1 CHINA 130
- 13.1.2 INDIA 136
- 13.1.3 JAPAN 142
- 13.1.4 INDONESIA 148
- 13.1.5 PHILIPPINES 154
- 13.1.6 THAILAND 160
- 13.1.7 AUSTRALIA 166
- 13.1.8 MALAYSIA 172
- 13.1.9 SOUTH KOREA 178
- 13.1.10 SINGAPORE 184
- 13.1.11 REST OF ASIA-PACIFIC 190

14 ASIA PACIFIC BREAST CANCER DIAGNOSTICS MARKET, COMPANY LANDSCAPE 191

14.1 COMPANY SHARE ANALYSIS: ASIA PACIFIC 191

15 SWOT ANALYSIS 192

16 COMPANY PROFILE 193

16.1 HOLOGIC, INC. 193
- 16.1.1 COMPANY SNAPSHOT 193
- 16.1.2 REVENUE ANALYSIS 193
- 16.1.3 COMPANY SHARE ANALYSIS 194
- 16.1.4 PRODUCT PORTFOLIO 194
- 16.1.5 RECENT DEVELOPMENTS 195
16.2 SIEMENS HEALTHCARE GMBH 196
- 16.2.1 COMPANY SNAPSHOT 196
- 16.2.2 REVENUE ANALYSIS 197
- 16.2.3 COMPANY SHARE ANALYSIS 197
- 16.2.4 PRODUCT PORTFOLIO 198
- 16.2.5 RECENT DEVELOPMENTS 198
16.3 F. HOFFMANN- LA ROCHE LTD 199
- 16.3.1 COMPANY SNAPSHOT 199
- 16.3.2 REVENUE ANALYSIS 199
- 16.3.3 COMPANY SHARE ANALYSIS 200
- 16.3.4 PRODUCT PORTFOLIO 200
- 16.3.5 RECENT DEVELOPMENTS 201
16.4 KONINKLIJKE PHILIPS N.V. 202
- 16.4.1 COMPANY SNAPSHOT 202
- 16.4.2 REVENUE ANALYSIS 202
- 16.4.3 COMPANY SHARE ANALYSIS 203
- 16.4.4 PRODUCT PORTFOLIO 203
- 16.4.5 RECENT DEVELOPMENTS 204
16.5 ABBOTT 205
- 16.5.1 COMPANY SNAPSHOT 205
- 16.5.2 REVENUE ANALYSIS 205
- 16.5.3 COMPANY SHARE ANALYSIS 206
- 16.5.4 PRODUCT PORTFOLIO 206
- 16.5.5 RECENT DEVELOPMENTS 206
16.6 ABACUS ALS 207
- 16.6.1 COMPANY SNAPSHOT 207
- 16.6.2 PRODUCT PORTFOLIO 207
- 16.6.3 RECENT DEVELOPMENTS 207
16.7 BD 208
- 16.7.1 COMPANY SNAPSHOT 208
- 16.7.2 REVENUE ANALYSIS 208
- 16.7.3 COMPANY SHARE ANALYSIS 209
- 16.7.4 PRODUCT PORTFOLIO 209
- 16.7.5 RECENT DEVELOPMENTS 209
16.8 BIOCEPT, INC. 210
- 16.8.1 COMPANY SNAPSHOT 210
- 16.8.2 REVENUE ANALYSIS 210
- 16.8.3 PRODUCT PORTFOLIO 211
- 16.8.4 RECENT DEVELOPMENTS 211
16.9 BIOMERIEUX 212
- 16.9.1 COMPANY SNAPSHOT 212
- 16.9.2 REVENUE ANALYSIS 212
- 16.9.3 PRODUCT PORTFOLIO 213
- 16.9.4 RECENT DEVELOPMENTS 213
16.10 BIO-RAD LABORATORIES, INC. 214
- 16.10.1 COMPANY SNAPSHOT 214
- 16.10.2 REVENUE ANALYSIS 214
- 16.10.3 PRODUCT PORTFOLIO 215
- 16.10.4 RECENT DEVELOPMENT 215
16.11 CEPHEID 216
- 16.11.1 COMPANY SNAPSHOT 216
- 16.11.2 REVENUE ANALYSIS 216
- 16.11.3 PRODUCT PORTFOLIO 217
- 16.11.4 RECENT DEVELOPMENT 217
16.12 EXACT SCIENCES CORPORATION 218
- 16.12.1 COMPANY SNAPSHOT 218
- 16.12.2 REVENUE ANALYSIS 218
- 16.12.3 COMPANY SHARE ANALYSIS 219
- 16.12.4 PRODUCT PORTFOLIO 219
- 16.12.5 RECENT DEVELOPMENTS 220
16.13 FUJIFILM CORPORATION 221
- 16.13.1 COMPANY SNAPSHOT 221
- 16.13.2 REVENUE ANALYSIS 221
- 16.13.3 PRODUCT PORTFOLIO 222
- 16.13.4 RECENT DEVELOPMENT 222
16.14 GENERAL ELECTRIC 223
- 16.14.1 COMPANY SNAPSHOT 223
- 16.14.2 REVENUE ANALYSIS 223
- 16.14.3 PRODUCT PORTFOLIO 224
- 16.14.4 RECENT DEVELOPMENTS 224
16.15 ILLUMINA, INC. 225
- 16.15.1 COMPANY SNAPSHOT 225
- 16.15.2 REVENUE ANALYSIS 225
- 16.15.3 PRODUCT PORTFOLIO 226
- 16.15.4 RECENT DEVELOPMENTS 226
16.16 MYRIAD GENETICS, INC. 227
- 16.16.1 COMPANY SNAPSHOT 227
- 16.16.2 REVENUE ANALYSIS 227
- 16.16.3 PRODUCT PORTFOLIO 228
- 16.16.4 RECENT DEVELOPMENT 228
16.17 NANOSTRING. 229
- 16.17.1 COMPANY SNAPSHOT 229
- 16.17.2 REVENUE ANALYSIS 229
- 16.17.3 PRODUCT PORTFOLIO 230
- 16.17.4 RECENT DEVELOPMENT 230
- 16.17.5 RECENT DEVELOPMENT 230
16.18 ONCOSTEM. 231
- 16.18.1 COMPANY SNAPSHOT 231
- 16.18.2 PRODUCT PORTFOLIO 231
- 16.18.3 RECENT DEVELOPMENT 231
16.19 PROVISTA DIAGNOSTICS. 232
- 16.19.1 COMPANY SNAPSHOT 232
- 16.19.2 PRODUCT PORTFOLIO 232
- 16.19.3 RECENT DEVELOPMENT 232
16.20 THERMO FISHER SCIENTIFIC INC. 233
- 16.20.1 COMPANY SNAPSHOT 233
- 16.20.2 REVENUE ANALYSIS 233
- 16.20.3 PRODUCT PORTFOLIO 234
- 16.20.4 RECENT DEVELOPMENT 234

17 QUESTIONNAIRE 235

18 RELATED REPORTS 238

LIST OF TABLES

TABLE 1 INCIDENCE RATE OF BREAST CANCER (2020) 49
TABLE 2 MORTALITY RATE OF BREAST CANCER (2020) 49
TABLE 3 INCIDENCE OF DUCTAL CARCINOMA IN SITU (DCIS) BREAST CANCER 49
TABLE 4 ASIA PACIFIC BREAST CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION) 64
TABLE 5 ASIA PACIFIC IMAGING IN BREAST CANCER DIAGNOSTICS MARKET, BY REGION, 2021-2030 (USD MILLION) 65
TABLE 6 ASIA PACIFIC IMAGING IN BREAST CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION) 65
TABLE 7 ASIA PACIFIC IONIZING BREAST IMAGING TECHNOLOGIES IN BREAST CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION) 66
TABLE 8 ASIA PACIFIC IONIZING BREAST IMAGING TECHNOLOGIES IN BREAST CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (UNITS) 66
TABLE 9 ASIA PACIFIC NON-IONIZING IMAGING TECHNOLOGIES IN BREAST CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION) 68
TABLE 10 ASIA PACIFIC NON-IONIZING IMAGING TECHNOLOGIES IN BREAST CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (UNITS) 68
TABLE 11 ASIA PACIFIC BIOPSY IN BREAST CANCER DIAGNOSTICS MARKET, BY REGION, 2021-2030 (USD MILLION) 69
TABLE 12 ASIA PACIFIC BIOPSY IN BREAST CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION) 70
TABLE 13 ASIA PACIFIC BIOPSY IN BREAST CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (UNITS) 70
TABLE 14 ASIA PACIFIC GENOMIC TEST IN BREAST CANCER DIAGNOSTICS MARKET, BY REGION, 2021-2030 (USD MILLION) 71
TABLE 15 ASIA PACIFIC GENOMIC TEST IN BREAST CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION) 72
TABLE 16 ASIA PACIFIC GENOMIC TEST IN BREAST CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (UNITS) 72
TABLE 17 ASIA PACIFIC MOLECULAR TESTING IN BREAST CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION) 72
TABLE 18 ASIA PACIFIC MOLECULAR TESTING IN BREAST CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (UNITS) 73
TABLE 19 ASIA PACIFIC BLOOD TEST IN BREAST CANCER DIAGNOSTICS MARKET, BY REGION, 2021-2030 (USD MILLION) 74
TABLE 20 ASIA PACIFIC OTHERS IN BREAST CANCER DIAGNOSTICS MARKET, BY REGION, 2021-2030 (USD MILLION) 75
TABLE 21 ASIA PACIFIC BREAST CANCER DIAGNOSTICS MARKET, BY TYPE, 2021-2030 (USD MILLION) 79
TABLE 22 ASIA PACIFIC INVASIVE DUCTAL CARCINOMA IN BREAST CANCER DIAGNOSTICS MARKET, BY REGION, 2021-2030 (USD MILLION) 80
TABLE 23 ASIA PACIFIC DUCTAL CARCINOMA IN SITU IN BREAST CANCER DIAGNOSTICS MARKET, BY REGION, 2021-2030 (USD MILLION) 81
TABLE 24 ASIA PACIFIC INFLAMMATORY BREAST CANCER IN BREAST CANCER DIAGNOSTICS MARKET, BY REGION, 2021-2030 (USD MILLION) 82
TABLE 25 ASIA PACIFIC METASTATIC BREAST CANCER IN BREAST CANCER DIAGNOSTICS MARKET, BY REGION, 2021-2030 (USD MILLION) 82
TABLE 26 ASIA PACIFIC BREAST CANCER DIAGNOSTICS MARKET, BY END USER, 2021-2030 (USD MILLION) 86
TABLE 27 ASIA PACIFIC HOSPITALS IN BREAST CANCER DIAGNOSTICS MARKET, BY REGION, 2021-2030 (USD MILLION) 87
TABLE 28 ASIA PACIFIC DIAGNOSTIC CENTERS IN BREAST CANCER DIAGNOSTICS MARKET, BY REGION, 2021-2030 (USD MILLION) 87
TABLE 29 ASIA PACIFIC CLINICS IN BREAST CANCER DIAGNOSTICS MARKET, BY REGION, 2021-2030 (USD MILLION) 88
TABLE 30 ASIA PACIFIC RESEARCH AND ACADEMIC INSTITUTES IN BREAST CANCER DIAGNOSTICS MARKET, BY REGION, 2021-2030 (USD MILLION) 89
TABLE 31 ASIA PACIFIC OTHERS IN BREAST CANCER DIAGNOSTICS MARKET, BY REGION, 2021-2030 (USD MILLION) 90
TABLE 32 ASIA PACIFIC BREAST CANCER DIAGNOSTICS MARKET, BY DISTRIBUTION CHANNEL, 2021-2030 (USD MILLION) 94
TABLE 33 ASIA PACIFIC DIRECT TENDER IN BREAST CANCER DIAGNOSTICS MARKET, BY REGION, 2021-2030 (USD MILLION) 95
TABLE 34 ASIA PACIFIC RETAIL SALES IN BREAST CANCER DIAGNOSTICS MARKET, BY REGION, 2021-2030 (USD MILLION) 96
TABLE 35 ASIA PACIFIC OTHERS IN BREAST CANCER DIAGNOSTICS MARKET, BY REGION, 2021-2030 (USD MILLION) 96
TABLE 36 ASIA-PACIFIC BREAST CANCER DIAGNOSTICS MARKET, BY COUNTRY, 2021-2030 (USD MILLION) 102
TABLE 37 ASIA-PACIFIC BREAST CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION) 102
TABLE 38 ASIA-PACIFIC IMAGING IN BREAST CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION) 102
TABLE 39 ASIA-PACIFIC IONIZING BREAST IMAGING TECHNOLOGIES IN BREAST CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION) 103
TABLE 40 ASIA-PACIFIC IONIZING BREAST IMAGING TECHNOLOGIES IN BREAST CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (UNITS) 103
TABLE 41 ASIA-PACIFIC NON-IONIZING IMAGING TECHNOLOGIES IN BREAST CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION) 103
TABLE 42 ASIA-PACIFIC NON-IONIZING IMAGING TECHNOLOGIES IN BREAST CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (UNITS) 104
TABLE 43 ASIA-PACIFIC BIOPSY IN BREAST CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION) 104
TABLE 44 ASIA-PACIFIC BIOPSY IN BREAST CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (UNITS) 104
TABLE 45 ASIA-PACIFIC GENOMIC TEST IN BREAST CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION) 104
TABLE 46 ASIA-PACIFIC GENOMIC TEST IN BREAST CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (UNITS) 105
TABLE 47 ASIA-PACIFIC MOLECULAR TESTING IN BREAST CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION) 105
TABLE 48 ASIA-PACIFIC MOLECULAR TESTING IN BREAST CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (UNITS) 105
TABLE 49 ASIA-PACIFIC BREAST CANCER DIAGNOSTICS MARKET, BY TYPE, 2021-2030 (USD MILLION) 105
TABLE 50 ASIA-PACIFIC BREAST CANCER DIAGNOSTICS MARKET, BY END USER, 2021-2030 (USD MILLION) 106
TABLE 51 ASIA-PACIFIC BREAST CANCER DIAGNOSTICS MARKET, BY DISTRIBUTION CHANNEL, 2021-2030 (USD MILLION) 106
TABLE 52 CHINA BREAST CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION) 107
TABLE 53 CHINA IMAGING IN BREAST CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION) 107
TABLE 54 CHINA IONIZING BREAST IMAGING TECHNOLOGIES IN BREAST CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION) 107
TABLE 55 CHINA IONIZING BREAST IMAGING TECHNOLOGIES IN BREAST CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 ASP 108
TABLE 56 CHINA IONIZING BREAST IMAGING TECHNOLOGIES IN BREAST CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (UNITS) 108
TABLE 57 CHINA NON-IONIZING IMAGING TECHNOLOGIES IN BREAST CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION) 108
TABLE 58 CHINA NON-IONIZING IMAGING TECHNOLOGIES IN BREAST CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 ASP 109
TABLE 59 CHINA NON-IONIZING IMAGING TECHNOLOGIES IN BREAST CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (UNITS) 109
TABLE 60 CHINA BIOPSY IN BREAST CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION) 109
TABLE 61 CHINA BIOPSY IN BREAST CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 ASP 109
TABLE 62 CHINA BIOPSY IN BREAST CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (UNITS) 110
TABLE 63 CHINA GENOMIC TEST IN BREAST CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION) 110
TABLE 64 CHINA GENOMIC TEST IN BREAST CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 ASP 110
TABLE 65 CHINA GENOMIC TEST IN BREAST CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (UNITS) 110
TABLE 66 CHINA MOLECULAR TESTING IN BREAST CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION) 110
TABLE 67 CHINA MOLECULAR TESTING IN BREAST CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 ASP 111
TABLE 68 CHINA MOLECULAR TESTING IN BREAST CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (UNITS) 111
TABLE 69 CHINA BREAST CANCER DIAGNOSTICS MARKET, BY TYPE, 2021-2030 (USD MILLION) 111
TABLE 70 CHINA BREAST CANCER DIAGNOSTICS MARKET, BY END USER, 2021-2030 (USD MILLION) 111
TABLE 71 CHINA BREAST CANCER DIAGNOSTICS MARKET, BY DISTRIBUTION CHANNEL, 2021-2030 (USD MILLION) 112
TABLE 72 INDIA BREAST CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION) 113
TABLE 73 INDIA IMAGING IN BREAST CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION) 113
TABLE 74 INDIA IONIZING BREAST IMAGING TECHNOLOGIES IN BREAST CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION) 113
TABLE 75 INDIA IONIZING BREAST IMAGING TECHNOLOGIES IN BREAST CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 ASP 114
TABLE 76 INDIA IONIZING BREAST IMAGING TECHNOLOGIES IN BREAST CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (UNITS) 114
TABLE 77 INDIA NON-IONIZING IMAGING TECHNOLOGIES IN BREAST CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION) 114
TABLE 78 INDIA NON-IONIZING IMAGING TECHNOLOGIES IN BREAST CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 ASP 115
TABLE 79 INDIA NON-IONIZING IMAGING TECHNOLOGIES IN BREAST CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (UNITS) 115
TABLE 80 INDIA BIOPSY IN BREAST CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION) 115
TABLE 81 INDIA BIOPSY IN BREAST CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 ASP 115
TABLE 82 INDIA BIOPSY IN BREAST CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (UNITS) 116
TABLE 83 INDIA GENOMIC TEST IN BREAST CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION) 116
TABLE 84 INDIA GENOMIC TEST IN BREAST CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 ASP 116
TABLE 85 INDIA GENOMIC TEST IN BREAST CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (UNITS) 116
TABLE 86 INDIA MOLECULAR TESTING IN BREAST CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION) 116
TABLE 87 INDIA MOLECULAR TESTING IN BREAST CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 ASP 117
TABLE 88 INDIA MOLECULAR TESTING IN BREAST CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (UNITS) 117
TABLE 89 INDIA BREAST CANCER DIAGNOSTICS MARKET, BY TYPE, 2021-2030 (USD MILLION) 117
TABLE 90 INDIA BREAST CANCER DIAGNOSTICS MARKET, BY END USER, 2021-2030 (USD MILLION) 117
TABLE 91 INDIA BREAST CANCER DIAGNOSTICS MARKET, BY DISTRIBUTION CHANNEL, 2021-2030 (USD MILLION) 118
TABLE 92 JAPAN BREAST CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION) 119
TABLE 93 JAPAN IMAGING IN BREAST CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION) 119
TABLE 94 JAPAN IONIZING BREAST IMAGING TECHNOLOGIES IN BREAST CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION) 119
TABLE 95 JAPAN IONIZING BREAST IMAGING TECHNOLOGIES IN BREAST CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 ASP 120
TABLE 96 JAPAN IONIZING BREAST IMAGING TECHNOLOGIES IN BREAST CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (UNITS) 120
TABLE 97 JAPAN NON-IONIZING IMAGING TECHNOLOGIES IN BREAST CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION) 120
TABLE 98 JAPAN NON-IONIZING IMAGING TECHNOLOGIES IN BREAST CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 ASP 121
TABLE 99 JAPAN NON-IONIZING IMAGING TECHNOLOGIES IN BREAST CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (UNITS) 121
TABLE 100 JAPAN BIOPSY IN BREAST CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION) 121
TABLE 101 JAPAN BIOPSY IN BREAST CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 ASP 121
TABLE 102 JAPAN BIOPSY IN BREAST CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (UNITS) 122
TABLE 103 JAPAN GENOMIC TEST IN BREAST CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION) 122
TABLE 104 JAPAN GENOMIC TEST IN BREAST CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 ASP 122
TABLE 105 JAPAN GENOMIC TEST IN BREAST CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (UNITS) 122
TABLE 106 JAPAN MOLECULAR TESTING IN BREAST CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION) 122
TABLE 107 JAPAN MOLECULAR TESTING IN BREAST CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 ASP 123
TABLE 108 JAPAN MOLECULAR TESTING IN BREAST CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (UNITS) 123
TABLE 109 JAPAN BREAST CANCER DIAGNOSTICS MARKET, BY TYPE, 2021-2030 (USD MILLION) 123
TABLE 110 JAPAN BREAST CANCER DIAGNOSTICS MARKET, BY END USER, 2021-2030 (USD MILLION) 123
TABLE 111 JAPAN BREAST CANCER DIAGNOSTICS MARKET, BY DISTRIBUTION CHANNEL, 2021-2030 (USD MILLION) 124
TABLE 112 INDONESIA BREAST CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION) 125
TABLE 113 INDONESIA IMAGING IN BREAST CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION) 125
TABLE 114 INDONESIA IONIZING BREAST IMAGING TECHNOLOGIES IN BREAST CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION) 125
TABLE 115 INDONESIA IONIZING BREAST IMAGING TECHNOLOGIES IN BREAST CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 ASP 126
TABLE 116 INDONESIA IONIZING BREAST IMAGING TECHNOLOGIES IN BREAST CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (UNITS) 126
TABLE 117 INDONESIA NON-IONIZING IMAGING TECHNOLOGIES IN BREAST CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION) 126
TABLE 118 INDONESIA NON-IONIZING IMAGING TECHNOLOGIES IN BREAST CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 ASP 127
TABLE 119 INDONESIA NON-IONIZING IMAGING TECHNOLOGIES IN BREAST CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (UNITS) 127
TABLE 120 INDONESIA BIOPSY IN BREAST CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION) 127
TABLE 121 INDONESIA BIOPSY IN BREAST CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 ASP 127
TABLE 122 INDONESIA BIOPSY IN BREAST CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (UNITS) 128
TABLE 123 INDONESIA GENOMIC TEST IN BREAST CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION) 128
TABLE 124 INDONESIA GENOMIC TEST IN BREAST CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 ASP 128
TABLE 125 INDONESIA GENOMIC TEST IN BREAST CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (UNITS) 128
TABLE 126 INDONESIA MOLECULAR TESTING IN BREAST CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION) 128
TABLE 127 INDONESIA MOLECULAR TESTING IN BREAST CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 ASP 129
TABLE 128 INDONESIA MOLECULAR TESTING IN BREAST CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (UNITS) 129
TABLE 129 INDONESIA BREAST CANCER DIAGNOSTICS MARKET, BY TYPE, 2021-2030 (USD MILLION) 129
TABLE 130 INDONESIA BREAST CANCER DIAGNOSTICS MARKET, BY END USER, 2021-2030 (USD MILLION) 129
TABLE 131 INDONESIA BREAST CANCER DIAGNOSTICS MARKET, BY DISTRIBUTION CHANNEL, 2021-2030 (USD MILLION) 130
TABLE 132 PHILIPPINES BREAST CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION) 131
TABLE 133 PHILIPPINES IMAGING IN BREAST CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION) 131
TABLE 134 PHILIPPINES IONIZING BREAST IMAGING TECHNOLOGIES IN BREAST CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION) 131
TABLE 135 PHILIPPINES IONIZING BREAST IMAGING TECHNOLOGIES IN BREAST CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 ASP 132
TABLE 136 PHILIPPINES IONIZING BREAST IMAGING TECHNOLOGIES IN BREAST CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (UNITS) 132
TABLE 137 PHILIPPINES NON-IONIZING IMAGING TECHNOLOGIES IN BREAST CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION) 132
TABLE 138 PHILIPPINES NON-IONIZING IMAGING TECHNOLOGIES IN BREAST CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 ASP 133
TABLE 139 PHILIPPINES NON-IONIZING IMAGING TECHNOLOGIES IN BREAST CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (UNITS) 133
TABLE 140 PHILIPPINES BIOPSY IN BREAST CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION) 133
TABLE 141 PHILIPPINES BIOPSY IN BREAST CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 ASP 133
TABLE 142 PHILIPPINES BIOPSY IN BREAST CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (UNITS) 134
TABLE 143 PHILIPPINES GENOMIC TEST IN BREAST CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION) 134
TABLE 144 PHILIPPINES GENOMIC TEST IN BREAST CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 ASP 134
TABLE 145 PHILIPPINES GENOMIC TEST IN BREAST CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (UNITS) 134
TABLE 146 PHILIPPINES MOLECULAR TESTING IN BREAST CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION) 134
TABLE 147 PHILIPPINES MOLECULAR TESTING IN BREAST CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 ASP 135
TABLE 148 PHILIPPINES MOLECULAR TESTING IN BREAST CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (UNITS) 135
TABLE 149 PHILIPPINES BREAST CANCER DIAGNOSTICS MARKET, BY TYPE, 2021-2030 (USD MILLION) 135
TABLE 150 PHILIPPINES BREAST CANCER DIAGNOSTICS MARKET, BY END USER, 2021-2030 (USD MILLION) 135
TABLE 151 PHILIPPINES BREAST CANCER DIAGNOSTICS MARKET, BY DISTRIBUTION CHANNEL, 2021-2030 (USD MILLION) 136
TABLE 152 THAILAND BREAST CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION) 137
TABLE 153 THAILAND IMAGING IN BREAST CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION) 137
TABLE 154 THAILAND IONIZING BREAST IMAGING TECHNOLOGIES IN BREAST CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION) 137
TABLE 155 THAILAND IONIZING BREAST IMAGING TECHNOLOGIES IN BREAST CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 ASP 138
TABLE 156 THAILAND IONIZING BREAST IMAGING TECHNOLOGIES IN BREAST CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (UNITS) 138
TABLE 157 THAILAND NON-IONIZING IMAGING TECHNOLOGIES IN BREAST CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION) 138
TABLE 158 THAILAND NON-IONIZING IMAGING TECHNOLOGIES IN BREAST CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 ASP 139
TABLE 159 THAILAND NON-IONIZING IMAGING TECHNOLOGIES IN BREAST CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (UNITS) 139
TABLE 160 THAILAND BIOPSY IN BREAST CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION) 139
TABLE 161 THAILAND BIOPSY IN BREAST CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 ASP 139
TABLE 162 THAILAND BIOPSY IN BREAST CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (UNITS) 140
TABLE 163 THAILAND GENOMIC TEST IN BREAST CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION) 140
TABLE 164 THAILAND GENOMIC TEST IN BREAST CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 ASP 140
TABLE 165 THAILAND GENOMIC TEST IN BREAST CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (UNITS) 140
TABLE 166 THAILAND MOLECULAR TESTING IN BREAST CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION) 140
TABLE 167 THAILAND MOLECULAR TESTING IN BREAST CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 ASP 141
TABLE 168 THAILAND MOLECULAR TESTING IN BREAST CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (UNITS) 141
TABLE 169 THAILAND BREAST CANCER DIAGNOSTICS MARKET, BY TYPE, 2021-2030 (USD MILLION) 141
TABLE 170 THAILAND BREAST CANCER DIAGNOSTICS MARKET, BY END USER, 2021-2030 (USD MILLION) 141
TABLE 171 THAILAND BREAST CANCER DIAGNOSTICS MARKET, BY DISTRIBUTION CHANNEL, 2021-2030 (USD MILLION) 142
TABLE 172 AUSTRALIA BREAST CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION) 143
TABLE 173 AUSTRALIA IMAGING IN BREAST CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION) 143
TABLE 174 AUSTRALIA IONIZING BREAST IMAGING TECHNOLOGIES IN BREAST CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION) 143
TABLE 175 AUSTRALIA IONIZING BREAST IMAGING TECHNOLOGIES IN BREAST CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 ASP 144
TABLE 176 AUSTRALIA IONIZING BREAST IMAGING TECHNOLOGIES IN BREAST CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (UNITS) 144
TABLE 177 AUSTRALIA NON-IONIZING IMAGING TECHNOLOGIES IN BREAST CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION) 144
TABLE 178 AUSTRALIA NON-IONIZING IMAGING TECHNOLOGIES IN BREAST CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 ASP 145
TABLE 179 AUSTRALIA NON-IONIZING IMAGING TECHNOLOGIES IN BREAST CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (UNITS) 145
TABLE 180 AUSTRALIA BIOPSY IN BREAST CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION) 145
TABLE 181 AUSTRALIA BIOPSY IN BREAST CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 ASP 145

TABLE 182 AUSTRALIA BIOPSY IN BREAST CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (UNITS) 146
TABLE 183 AUSTRALIA GENOMIC TEST IN BREAST CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION) 146
TABLE 184 AUSTRALIA GENOMIC TEST IN BREAST CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 ASP 146
TABLE 185 AUSTRALIA GENOMIC TEST IN BREAST CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (UNITS) 146
TABLE 186 AUSTRALIA MOLECULAR TESTING IN BREAST CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION) 146
TABLE 187 AUSTRALIA MOLECULAR TESTING IN BREAST CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 ASP 147
TABLE 188 AUSTRALIA MOLECULAR TESTING IN BREAST CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (UNITS) 147
TABLE 189 AUSTRALIA BREAST CANCER DIAGNOSTICS MARKET, BY TYPE, 2021-2030 (USD MILLION) 147
TABLE 190 AUSTRALIA BREAST CANCER DIAGNOSTICS MARKET, BY END USER, 2021-2030 (USD MILLION) 147
TABLE 191 AUSTRALIA BREAST CANCER DIAGNOSTICS MARKET, BY DISTRIBUTION CHANNEL, 2021-2030 (USD MILLION) 148
TABLE 192 MALAYSIA BREAST CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION) 149
TABLE 193 MALAYSIA IMAGING IN BREAST CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION) 149
TABLE 194 MALAYSIA IONIZING BREAST IMAGING TECHNOLOGIES IN BREAST CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION) 149
TABLE 195 MALAYSIA IONIZING BREAST IMAGING TECHNOLOGIES IN BREAST CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 ASP 150
TABLE 196 MALAYSIA IONIZING BREAST IMAGING TECHNOLOGIES IN BREAST CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (UNITS) 150
TABLE 197 MALAYSIA NON-IONIZING IMAGING TECHNOLOGIES IN BREAST CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION) 150
TABLE 198 MALAYSIA NON-IONIZING IMAGING TECHNOLOGIES IN BREAST CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 ASP 151
TABLE 199 MALAYSIA NON-IONIZING IMAGING TECHNOLOGIES IN BREAST CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (UNITS) 151
TABLE 200 MALAYSIA BIOPSY IN BREAST CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION) 151
TABLE 201 MALAYSIA BIOPSY IN BREAST CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 ASP 151
TABLE 202 MALAYSIA BIOPSY IN BREAST CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (UNITS) 152
TABLE 203 MALAYSIA GENOMIC TEST IN BREAST CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION) 152
TABLE 204 MALAYSIA GENOMIC TEST IN BREAST CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 ASP 152
TABLE 205 MALAYSIA GENOMIC TEST IN BREAST CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (UNITS) 152
TABLE 206 MALAYSIA MOLECULAR TESTING IN BREAST CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION) 152
TABLE 207 MALAYSIA MOLECULAR TESTING IN BREAST CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 ASP 153
TABLE 208 MALAYSIA MOLECULAR TESTING IN BREAST CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (UNITS) 153
TABLE 209 MALAYSIA BREAST CANCER DIAGNOSTICS MARKET, BY TYPE, 2021-2030 (USD MILLION) 153
TABLE 210 MALAYSIA BREAST CANCER DIAGNOSTICS MARKET, BY END USER, 2021-2030 (USD MILLION) 153
TABLE 211 MALAYSIA BREAST CANCER DIAGNOSTICS MARKET, BY DISTRIBUTION CHANNEL, 2021-2030 (USD MILLION) 154
TABLE 212 SOUTH KOREA BREAST CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION) 155
TABLE 213 SOUTH KOREA IMAGING IN BREAST CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION) 155
TABLE 214 SOUTH KOREA IONIZING BREAST IMAGING TECHNOLOGIES IN BREAST CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION) 155
TABLE 215 SOUTH KOREA IONIZING BREAST IMAGING TECHNOLOGIES IN BREAST CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 ASP 156
TABLE 216 SOUTH KOREA IONIZING BREAST IMAGING TECHNOLOGIES IN BREAST CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (UNITS) 156
TABLE 217 SOUTH KOREA NON-IONIZING IMAGING TECHNOLOGIES IN BREAST CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION) 156
TABLE 218 SOUTH KOREA NON-IONIZING IMAGING TECHNOLOGIES IN BREAST CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 ASP 157
TABLE 219 SOUTH KOREA NON-IONIZING IMAGING TECHNOLOGIES IN BREAST CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (UNITS) 157
TABLE 220 SOUTH KOREA BIOPSY IN BREAST CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION) 157
TABLE 221 SOUTH KOREA BIOPSY IN BREAST CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 ASP 157
TABLE 222 SOUTH KOREA BIOPSY IN BREAST CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (UNITS) 158
TABLE 223 SOUTH KOREA GENOMIC TEST IN BREAST CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION) 158
TABLE 224 SOUTH KOREA GENOMIC TEST IN BREAST CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 ASP 158
TABLE 225 SOUTH KOREA GENOMIC TEST IN BREAST CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (UNITS) 158
TABLE 226 SOUTH KOREA MOLECULAR TESTING IN BREAST CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION) 158
TABLE 227 SOUTH KOREA MOLECULAR TESTING IN BREAST CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 ASP 159
TABLE 228 SOUTH KOREA MOLECULAR TESTING IN BREAST CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (UNITS) 159
TABLE 229 SOUTH KOREA BREAST CANCER DIAGNOSTICS MARKET, BY TYPE, 2021-2030 (USD MILLION) 159
TABLE 230 SOUTH KOREA BREAST CANCER DIAGNOSTICS MARKET, BY END USER, 2021-2030 (USD MILLION) 159
TABLE 231 SOUTH KOREA BREAST CANCER DIAGNOSTICS MARKET, BY DISTRIBUTION CHANNEL, 2021-2030 (USD MILLION) 160
TABLE 232 SINGAPORE BREAST CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION) 161
TABLE 233 SINGAPORE IMAGING IN BREAST CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION) 161
TABLE 234 SINGAPORE IONIZING BREAST IMAGING TECHNOLOGIES IN BREAST CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION) 161
TABLE 235 SINGAPORE IONIZING BREAST IMAGING TECHNOLOGIES IN BREAST CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 ASP 162
TABLE 236 SINGAPORE IONIZING BREAST IMAGING TECHNOLOGIES IN BREAST CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (UNITS) 162
TABLE 237 SINGAPORE NON-IONIZING IMAGING TECHNOLOGIES IN BREAST CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION) 162
TABLE 238 SINGAPORE NON-IONIZING IMAGING TECHNOLOGIES IN BREAST CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 ASP 163
TABLE 239 SINGAPORE NON-IONIZING IMAGING TECHNOLOGIES IN BREAST CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (UNITS) 163
TABLE 240 SINGAPORE BIOPSY IN BREAST CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION) 163
TABLE 241 SINGAPORE BIOPSY IN BREAST CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 ASP 163
TABLE 242 SINGAPORE BIOPSY IN BREAST CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (UNITS) 164
TABLE 243 SINGAPORE GENOMIC TEST IN BREAST CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION) 164
TABLE 244 SINGAPORE GENOMIC TEST IN BREAST CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 ASP 164
TABLE 245 SINGAPORE GENOMIC TEST IN BREAST CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (UNITS) 164
TABLE 246 SINGAPORE MOLECULAR TESTING IN BREAST CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION) 164
TABLE 247 SINGAPORE MOLECULAR TESTING IN BREAST CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 ASP 165
TABLE 248 SINGAPORE MOLECULAR TESTING IN BREAST CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (UNITS) 165
TABLE 249 SINGAPORE BREAST CANCER DIAGNOSTICS MARKET, BY TYPE, 2021-2030 (USD MILLION) 165
TABLE 250 SINGAPORE BREAST CANCER DIAGNOSTICS MARKET, BY END USER, 2021-2030 (USD MILLION) 165
TABLE 251 SINGAPORE BREAST CANCER DIAGNOSTICS MARKET, BY DISTRIBUTION CHANNEL, 2021-2030 (USD MILLION) 166
TABLE 252 REST OF ASIA-PACIFIC BREAST CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION) 167

LIST OF FIGURES

FIGURE 1 ASIA PACIFIC BREAST CANCER DIAGNOSTIC MARKET: SEGMENTATION 30
FIGURE 2 ASIA PACIFIC BREAST CANCER DIAGNOSTIC MARKET: DATA TRIANGULATION 33
FIGURE 3 ASIA PACIFIC BREAST CANCER DIAGNOSTIC MARKET: DROC ANALYSIS 34
FIGURE 4 ASIA PACIFIC BREAST CANCER DIAGNOSTIC MARKET: ASIA PACIFIC VS REGIONAL MARKET ANALYSIS 35
FIGURE 5 ASIA PACIFIC BREAST CANCER DIAGNOSTIC MARKET: COMPANY RESEARCH ANALYSIS 35
FIGURE 6 ASIA PACIFIC BREAST CANCER DIAGNOSTIC MARKET: INTERVIEW DEMOGRAPHICS 36
FIGURE 7 ASIA PACIFIC BREAST CANCER DIAGNOSTIC MARKET: MARKET END USER COVERAGE GRID 38
FIGURE 8 ASIA PACIFIC BREAST CANCER DIAGNOSTIC MARKET: DBMR MARKET POSITION GRID 40
FIGURE 9 ASIA PACIFIC BREAST CANCER DIAGNOSTIC MARKET: VENDOR SHARE ANALYSIS 41
FIGURE 10 ASIA PACIFIC BREAST CANCER DIAGNOSTIC MARKET: SEGMENTATION 44
FIGURE 11 GROWING AWARENESS OF BREAST CANCER AND INCREASING HEALTHCARE EXPENDITURE IS EXPECTED TO DRIVE THE GROWTH OF THE ASIA PACIFIC BREAST CANCER DIAGNOSTIC MARKET FROM 2023 TO 2030 45
FIGURE 12 THE IMAGING SEGMENT IS EXPECTED TO ACCOUNT FOR THE LARGEST SHARE OF THE ASIA PACIFIC BREAST CANCER DIAGNOSTIC MARKET IN 2023 & 2030 45
FIGURE 13 DRIVERS, RESTRAINTS, OPPORTUNITIES, AND CHALLENGES OF THE ASIA PACIFIC BREAST CANCER DIAGNOSTICS MARKET 53
FIGURE 14 ASIA PACIFIC BREAST CANCER DIAGNOSTICS MARKET : BY TEST TYPE, 2022 61
FIGURE 15 ASIA PACIFIC BREAST CANCER DIAGNOSTICS MARKET : BY TEST TYPE, 2023-2030 (USD MILLION) 62
FIGURE 16 ASIA PACIFIC BREAST CANCER DIAGNOSTICS MARKET : BY TEST TYPE, CAGR (2023-2030) 62
FIGURE 17 ASIA PACIFIC BREAST CANCER DIAGNOSTICS MARKET : BY TEST TYPE, LIFELINE CURVE 63
FIGURE 18 ASIA PACIFIC BREAST CANCER DIAGNOSTICS MARKET : BY TYPE, 2022 76
FIGURE 19 ASIA PACIFIC BREAST CANCER DIAGNOSTICS MARKET : BY TYPE, 2023-2030 (USD MILLION) 77
FIGURE 20 ASIA PACIFIC BREAST CANCER DIAGNOSTICS MARKET : BY TYPE, CAGR (2023-2030) 77
FIGURE 21 ASIA PACIFIC BREAST CANCER DIAGNOSTICS MARKET : BY TYPE, LIFELINE CURVE 78
FIGURE 22 ASIA PACIFIC BREAST CANCER DIAGNOSTICS MARKET : BY END USER, 2022 83
FIGURE 23 ASIA PACIFIC BREAST CANCER DIAGNOSTICS MARKET : BY END USER, 2023-2030 (USD MILLION) 84
FIGURE 24 ASIA PACIFIC BREAST CANCER DIAGNOSTICS MARKET : BY END USER, CAGR (2023-2030) 84
FIGURE 25 ASIA PACIFIC BREAST CANCER DIAGNOSTICS MARKET : BY END USER, LIFELINE CURVE 85
FIGURE 26 ASIA PACIFIC BREAST CANCER DIAGNOSTICS MARKET : BY DISTRIBUTION CHANNEL, 2022 91
FIGURE 27 ASIA PACIFIC BREAST CANCER DIAGNOSTICS MARKET : BY DISTRIBUTION CHANNEL, 2023-2030 (USD MILLION) 92
FIGURE 28 ASIA PACIFIC BREAST CANCER DIAGNOSTICS MARKET : BY DISTRIBUTION CHANNEL, CAGR (2023-2030) 92
FIGURE 29 ASIA PACIFIC BREAST CANCER DIAGNOSTICS MARKET : BY DISTRIBUTION CHANNEL, LIFELINE CURVE 93
FIGURE 30 ASIA-PACIFIC BREAST CANCER DIAGNOSTICS MARKET: SNAPSHOT (2022) 98
FIGURE 31 ASIA-PACIFIC BREAST CANCER DIAGNOSTICS MARKET: BY COUNTRY (2022) 99
FIGURE 32 ASIA-PACIFIC BREAST CANCER DIAGNOSTICS MARKET: BY COUNTRY (2023 & 2030) 99
FIGURE 33 ASIA-PACIFIC BREAST CANCER DIAGNOSTICS MARKET: BY COUNTRY (2022 & 2030) 100
FIGURE 34 ASIA-PACIFIC BREAST CANCER DIAGNOSTICS MARKET: TEST TYPE (2023-2030) 100
FIGURE 35 ASIA PACIFIC BREAST CANCER DIAGNOSTICS MARKET: COMPANY SHARE 2022 (%) 167